IMP-1088
Based on 9 publication(s) in Google Scholar
IMP-1088 is a potent human N-myristoyltransferases NMT1 and NMT2 dual inhibitor with IC50s of <1 nM for HsNMT1 and HsNMT2. IMP-1088 has a Kd of <210 pM for HsNMT1. IMP-1088 efficiently blocks rhinovirus replication by blocking rhinovirus virus-encoded protein (VP0) N-myristoylation. IMP-1088 protects host cells from the cytotoxic effects of viral infection.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 98.25%
- No. CAS: 2059148-82-0
- Fòrmula: C25H29F2N5O
- Peso molecular:453.53
-
Almacenamiento:
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) IMP-1088
More- Nat Aging. 2026 Feb;6(2):316-328. [Abstract]
- Nat Commun. 2026 May 11. [Abstract]
- Nat Commun. 2026 Feb 12;17(1):1214. [Abstract]
- Redox Biol. 2024 Jul:73:103207. [Abstract]
- Mater Today Bio. 2026 Feb 18:37:102945. [Abstract]
- Pestic Biochem Physiol. 2025 Dec 22;218:106908.
- Cell Signal. 2023 Sep:109:110739. [Abstract]
- Norwegian University of Science and Technology. 2023 May.
- bioRxiv. 2023 Mar 3.
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
Bio/Physico-chemical Assay
-
WB
-
IF
-
IF
Ver todos los productos específicos de isoformas DNA/RNA Synthesis
More
Actividad biológica
IC50: <1 nM (HsNMT1) and <1 nM (HsNMT2)[1]
Kd: <210 pM (HsNMT1)[1]
IMP-1088 (1-1000 nM) prevents virus-induced cytopathic effect (CPE) in a dose-dependent manner with an IC50 of 17 nM. IMP-1088 (125 nM) complete suppresses of new infectious virus with an IC50 of 5.8 nM. IMP-1088 (1-1000 nM) blocks production of infectious virus and inhibits single cycle replication in primary human bronchial epithelial cells (hBEC) infected with rhinovirus RV-A1 (MOI 5) for 7 h. IMP-1088 significantly inhibits production of infectious virus even when added up to 3 hours post-infection[1].
IMP-1088 (50 nM) significantly less enriches multiple N-myristoylated proteins in enriched samples[1].
IMP-1088 (500 nM) inhibits production of infectious rhinovirus particles by blocking virus assembly in HeLa cells infected with rhinovirus RV-A16 (MOI 20) for 6 h[1].
IMP-1088 (0.24 nM-1 μM; for 24 hours +24 hours washout) has no long-term effect on cell viability and NMT activity fully recovers by 24 h[1].
IMP-1088 potently blocks a key step in viral capsid assembly by inhibition of co-translational myristoylation of a specific virus-encoded protein (VP0). IMP-1088 blocks neither production of viral RNA, nor translation of rhinovirus polyprotein[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
No. CAS 2059148-82-0
-
Appearance Solid
-
Peso molecular 453.53
-
Fòrmula C25H29F2N5O
-
Color White to light yellow
-
SMILES
CN1N=C(CN(C)C)C2=C1C=CC(C3=CC=C(F)C(F)=C3OCCC4=C(C)N(C)N=C4C)=C2
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (9)
-
Journal Impact Factor
-
Most Recent
-
Nat Aging
Comparative analysis of senolytic drugs reveals mitochondrial determinants of efficacy and resistance. [Abstract]2026 Feb;6(2):316-328. PMID: 41611832 -
Nat Commun
Inhibition of host N-myristoylation compromises the infectivity of SARS-CoV-2 due to Golgi-bypassing egress. [Abstract]2026 May 11. PMID: 42115621 -
Nat Commun
Human iPSC-based Modeling of Pulmonary Fibrosis Reveals p300/CBP Inhibition Suppresses Alveolar Transitional Cell State. [Abstract]2026 Feb 12;17(1):1214. PMID: 41680175 -
Redox Biol
Redistribution of defective mitochondria-mediated dihydroorotate dehydrogenase imparts 5-fluorouracil resistance in colorectal cancer. [Abstract]2024 Jul:73:103207. PMID: 38805974 -
Mater Today Bio
Application of a novel myristoylproteomics approach identifies GLIPR2 as a key pro-ferroptotic substrate in non-small cell lung cancer. [Abstract]2026 Feb 18:37:102945. PMID: 41782991
IMP-1088 purchased from MedChemExpress. Usage Cited in: Mater Today Bio. 2026 Feb 18:37:102945. [Abstract]
Viability of Calu-1 cells pretreated with DMSO or 1 μM IMP-1088, then exposed to erastin or ML162 ± Fer-1.
IMP-1088 purchased from MedChemExpress. Usage Cited in: Mater Today Bio. 2026 Feb 18:37:102945. [Abstract]
Volcano plot for Calu-1 cells shows YnMyr incorporation versus significance in the presence of IMP-1088. Confidence categories: high (blue), medium (green; circle, rhombus, triangle), low (yellow), potential (purple), non-substrates (gray).
IMP-1088 purchased from MedChemExpress. Usage Cited in: Mater Today Bio. 2026 Feb 18:37:102945. [Abstract]
Western blot analysis of GLIPR2 myristoylation in GLIPR2-knockout Calu-1 cells reconstituted as indicated, and treated with or without 1 μM IMP-1088.
-
-
Cell Signal
2023 Sep:109:110739. PMID: 37269961 -
-
IMP-1088 purchased from MedChemExpress. Usage Cited in: bioRxiv. 2023 Mar 3.
Representative immunofluorescence staining images of A549-AT lung cells treated with indicated concentrations of IMP-1088 (62.5 nM, 1 μM) or DMSO vehicle control, 1.5 hours before-infection (hbi) or post-infection (hpi) and infected with SARS-CoV-2 wuh for 24 h. Viral markers N (magenta) and dsRNA (yellow), actin (green) and nuclei (DAPI, blue).
IMP-1088 purchased from MedChemExpress. Usage Cited in: bioRxiv. 2023 Mar 3.
Representative immunofluorescence images and (E) quantification of SARS-CoV-2 wuh infection (normalized to number of nuclei) in A549-AT cells treated with indicated concentrations of IMP-1088 or DMSO vehicle control 1.5 hbi, infected with for 48 h and stained against N (magenta), actin (green), and nuclei (blue). The boxed areas i (multi-nucleated syncytium of cells), ii and iii (infected single cells) are shown magnified at the bottom of each image.
IMP-1088 purchased from MedChemExpress. Usage Cited in: bioRxiv. 2023 Mar 3.
Representative immunofluorescence images of human primary nasal epithelial cells grown as a pseudostratified columnar epithelium and treated with IMP-1088 (1 µM) or Nafamostat and Apilimod (20 µM and 0.25 µM, respectively) or DMSO vehicle control and infected with SARS-CoV-2 wuh for 72 h and stained against viral markers N (yellow), actin (magenta) and nuclei (cyan).
IMP-1088 purchased from MedChemExpress. Usage Cited in: bioRxiv. 2023 Mar 3.
Quantification of relative infection (number of GFP positive cells normalized to the number of nuclei) of RSV-GFP 24 hpi and 48 hpi (P), SFV-GFP at 12 hpi and 24 hpi (Q), and VSV-GFP at 12 hpi and 24 hpi (R), respectively, in DMSO and 0.01-1 µM IMP-1088 treated A549 cells (at 2 hbi or 1 hbi).
Solvente y solubilidad
DMSO : 100 mg/mL (220.49 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.51 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (5.51 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (278 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.2049 mL | 11.0246 mL | 22.0493 mL | 55.1231 mL |
| 5 mM | 0.4410 mL | 2.2049 mL | 4.4099 mL | 11.0246 mL | |
| 10 mM | 0.2205 mL | 1.1025 mL | 2.2049 mL | 5.5123 mL | |
| 15 mM | 0.1470 mL | 0.7350 mL | 1.4700 mL | 3.6749 mL | |
| 20 mM | 0.1102 mL | 0.5512 mL | 1.1025 mL | 2.7562 mL | |
| 25 mM | 0.0882 mL | 0.4410 mL | 0.8820 mL | 2.2049 mL | |
| 30 mM | 0.0735 mL | 0.3675 mL | 0.7350 mL | 1.8374 mL | |
| 40 mM | 0.0551 mL | 0.2756 mL | 0.5512 mL | 1.3781 mL | |
| 50 mM | 0.0441 mL | 0.2205 mL | 0.4410 mL | 1.1025 mL | |
| 60 mM | 0.0367 mL | 0.1837 mL | 0.3675 mL | 0.9187 mL | |
| 80 mM | 0.0276 mL | 0.1378 mL | 0.2756 mL | 0.6890 mL | |
| 100 mM | 0.0220 mL | 0.1102 mL | 0.2205 mL | 0.5512 mL |
IMP-1088 Related Classifications
HY-112258 Related Classifications
Powered by Bioz